Словения - словенский - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva pharma b.v. - simvastatin - filmsko obložena tableta - simvastatin 5 mg / 1 tableta - simvastatin

Словения - словенский - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva pharma b.v. - simvastatin - filmsko obložena tableta - simvastatin 40 mg / 1 tableta - simvastatin

Словения - словенский - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva pharma b.v. - kalcitriol - kapsula, mehka - kalcitriol 0,25 µg / 1 kapsula - kalcitriol

Словения - словенский - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva pharma b.v. - kalcitriol - kapsula, mehka - kalcitriol 0,5 µg / 1 kapsula - kalcitriol

Европейский союз - словенский - EMA (European Medicines Agency)

biogen idec ltd - daclizumab - multiple skleroza - imunosupresivi - zdravilo zinbryta je indicirano pri odraslih bolnikih za zdravljenje recidivnih oblik multiple skleroze (rms).

Европейский союз - словенский - EMA (European Medicines Agency)

biogen netherlands b.v. - nusinersen natrij - mišična atrofija, hrbtenica - druga zdravila na živčnem sistemu - zdravilo spinraza je indicirano za zdravljenje 5q spinal muscular atrophy.

Словения - словенский - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

chemicals laif -

Словения - словенский - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

chemicals laif -

Европейский союз - словенский - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multiple skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 in 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Европейский союз - словенский - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - multiplo sklerozo, recidivno-nakazila - imunosupresivi - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).